| Date | Action | Conf | Host / episode | Summary | 7d | 30d | 90d |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | MENTIONED | LOW | Rob Black Show Afternoon podcast 10-1-26 |
Named once as just under 1.5% of the S&P 500 in the index-weight list. [audio] | — | — | — |
| 2026-09-22 | WATCH | MEDIUM | Rob Black Show Markets Near High As Oil Falls |
Rob described Lilly as having the strongest obesity-treatment pipeline as Medicare coverage expanded use of Zepbound. [audio] | +1.2% | — | — |
| 2026-09-21 | MENTIONED | LOW | Rob Black Show Stocks Rise As Oil Prices Ease |
Eli Lilly was described as having taken the lead from Novo Nordisk in the weight-loss drug race. [audio] | +1.7% | — | — |
| 2026-09-15 | BUY | HIGH | Rob Black Show Markets Fall As Losses Accelerate |
Eli Lilly was upgraded to buy, with the thesis that it can retain its obesity-drug lead and grow through acquisitions. [audio] | +3.0% | — | — |
| 2026-09-14 | MENTIONED | LOW | Rob Black Show Major Shakeup In Artificial Intelligence Amid Safety Concerns |
Eli Lilly was cited as the obesity-drug market-share leader over Novo. [audio] | +2.3% | — | — |
| 2026-09-10 | WATCH | MEDIUM | Rob Black Show Stocks Dropped After Oil Prices Topped A Hundred A Barrel |
Rob singles out Eli Lilly's strong pipeline while discussing the healthcare group's improving appeal to investors. [audio] | +2.6% | — | — |
| 2026-09-01 | MENTIONED | MEDIUM | Rob Black Show Rough Start To September |
Lilly keeps redeploying its obesity drug windfall, making another acquisition to fund the next generation of drugs. [audio] | -3.1% | — | — |
| 2026-08-31 | WATCH | MEDIUM | Rob Black Show Afternoon podcast 8-31-26 |
Already under pressure to lower Zepbound pricing, and Trump is expected to announce new drug pricing deals with nearly a dozen drug makers heading into the midterms. [audio] | -0.6% | +0.3% | — |
| 2026-08-31 | WATCH | MEDIUM | Rob Black Show Stocks Fall After Strikes On Iran |
Lilly is buying Meridia Biosciences for up to $2.87 billion to build an immunology platform, and new Zepbound combination data showed dramatically better psoriasis outcomes, though the stock slipped on the deal. [audio] | -0.6% | +0.3% | — |
| 2026-08-27 | BUY | MEDIUM | Rob Black Show Nvidia Revenue Outlook Lifts Chip Stocks |
Rob said he has always liked Lilly more than Novo Nordisk because it has more drugs in its pipeline and is less dependent on GLP-1s. [audio] | -1.4% | +0.6% | — |
| 2026-08-12 | BUY | MEDIUM | Rob Black Show Tame Inflation Data |
Rob noted Lilly has already grabbed the lead in injectable obesity drugs, with investors watching who wins the next round of the weight loss pill battle. [audio] | +5.1% | -8.4% | — |
| 2026-08-06 | BUY | HIGH | Rob Black Show Traders Keep An Eye On The Middle East |
A really solid beat-and-raise quarter with Morgan Stanley, BMO and Wells Fargo all raising price targets; improving profitability and next-generation obesity drugs in focus. [audio] | +1.4% | -3.4% | — |
| 2026-08-05 | BUY | HIGH | Rob Black Show Afternoon podcast 8-5-26 |
Lilly delivered a blowout quarter with revenue near $23 billion up 48% and EPS of $8.38 versus $6 expected, and Rob framed it as transforming from a drugmaker into the world's leading metabolic health platform. [audio] | +4.3% | -1.6% | — |
| 2026-08-05 | BUY | HIGH | Rob Black Show Markets Rally To Fresh Records On Earnings Strength |
Lilly's stock soared after crushing second-quarter estimates and raising full-year guidance on unrelenting demand for Zepbound and Mounjaro, with an oral GLP-1 and retatrutide still ahead. [audio] | +4.3% | -1.6% | — |
| 2026-07-24 | BUY | HIGH | Rob Black Show Broader Market Rebounded |
Eli Lilly is discussed as a leader in diabetes and weight loss drugs; expected to benefit from FDA decisions and maintain pricing power. [audio] | -3.9% | +5.1% | — |
| 2026-07-23 | BUY | HIGH | Rob Black Show Markets Lower As Tech Disappoints |
Host expresses preference for Lilly over Novo Nordisk; discusses strong sales and aggressive expansion in obesity drugs. [audio] | -2.6% | +6.0% | — |
| 2026-07-20 | BUY | HIGH | Rob Black Show Oil Prices Fluctuated |
Eli Lilly acquiring a Thai Life Sciences due to successful GLP-1s; partnership with NVIDIA for AI drug discovery; cited as a big pharma player interested in psychedelics. [audio] | +4.4% | +11.8% | — |
| 2026-07-17 | MENTIONED | HIGH | Rob Black Show Financial Planning That You Never Knew |
Eli Lilly discussed for acquiring ATAI Life Sciences and its interest in psychedelic medicine. [audio] | +1.4% | +0.2% | — |
| 2026-07-16 | BUY | MEDIUM | Rob Black Show Afternoon podcast 7-16-26 |
Host notes Eli Lilly is staying busy, acquiring companies in psychedelics and depression treatment. [audio] | +1.4% | +1.1% | — |
| 2026-07-16 | BUY | HIGH | Rob Black Show Chip Stocks Weighing On The Market |
Eli Lilly is buying Atai Beckley in a deal valued up to $3.8 billion, betting on depression therapy. [audio] | +1.4% | +1.1% | — |
| 2026-07-09 | MENTIONED | LOW | Rob Black Show Stocks Rose Supported By Jump In Semiconductors |
Eli Lilly is near all-time highs, mentioned among drug makers. [audio] | -3.9% | -2.6% | — |
| 2026-06-29 | BUY | MEDIUM | Rob Black Show Afternoon podcast 6-29-26 |
Eli Lilly traded at all-time highs; positive sentiment implied. [audio] | -2.4% | -1.6% | -3.6% |
| 2026-06-26 | BUY | HIGH | Rob Black Show Big Picture Digging On This Week |
Recommends owning Eli Lilly for the long term due to its pharmaceutical moat. [audio] | +0.5% | -1.0% | -2.0% |
| 2026-06-23 | MENTIONED | LOW | Rob Black Show Global Chip Rout |
Eli Lilly is mentioned for its planned weight loss pill availability in Europe. [audio] | +8.3% | +7.1% | +5.4% |
| 2026-06-22 | MENTIONED | LOW | Rob Black Show Afternoon podcast 6-22-26 |
Eli Lilly's GLP-1 drugs mentioned as high-demand therapies. [audio] | +11.6% | +5.5% | +4.8% |
| 2026-06-12 | BUY | HIGH | Rob Black Show Afternoon podcast 6-12-26 |
Eli Lilly's weight loss drug Monjurno revenue rose 125% year over year, cited as a positive trend. [audio] | -3.0% | +4.9% | -0.7% |
| 2026-06-09 | MENTIONED | LOW | Rob Black Show Chip Stocks Lost Momentum |
Lilly is mentioned as an outperformer in healthcare sector. [audio] | -1.9% | +6.3% | +0.6% |
| 2026-06-08 | MENTIONED | LOW | Rob Black Show Afternoon podcast 6-8-26 |
Eli Lilly's new weight loss drug discussed as taking off 28% of your weight. [audio] | -1.7% | +5.8% | +0.2% |
| 2026-06-08 | BUY | MEDIUM | Rob Black Show Stocks Rebound From Friday Rout |
Lilly shares are rising today on hopes that the next generation drug will extend the lead in the weight loss market. [audio] | -1.7% | +5.8% | +0.2% |
| 2026-06-04 | MENTIONED | MEDIUM | Rob Black Show Broadcom Problems |
Eli Lilly is up 4.5% today. [audio] | +3.2% | +7.9% | +3.2% |
| 2026-05-27 | MENTIONED | HIGH | Rob Black Show Hopes Of Easing Iran Tensions |
Host mentions Eli Lilly acquiring vaccine developers for about $3.8 billion. [audio] | -0.4% | +11.6% | +14.1% |
| 2026-05-21 | BUY | HIGH | Rob Black Show Crude Prices Jumped |
Stock rose ~2% today despite a 5% YTD decline, driven by positive trial results for new GLP-1 drug RETA True Tide which showed superior weight loss compared to existing drugs. [audio] | +8.2% | +5.5% | +23.1% |
| 2026-05-20 | BUY | MEDIUM | Rob Black Show Afternoon podcast 5-20-26 |
Host expresses bullish sentiment on Eli Lilly (and Novo Nordisk) for their GLP-1 drugs that will save lives and extend longevity. [audio] | +6.3% | +7.8% | +20.5% |
| 2026-05-19 | MENTIONED | LOW | Rob Black Show Stocks Slide Under Pressure From Higher Rates |
Eli Lilly is listed as one of the pharmaceutical companies offering discounts on TrumpRx. [audio] | +4.2% | +7.6% | +16.0% |
| 2026-05-13 | MENTIONED | MEDIUM | Rob Black Show Afternoon podcast 5-13-26 |
Eli Lilly was mentioned in comparison to Micron in terms of market cap. [audio] | +0.5% | +11.7% | +19.8% |
| 2026-05-13 | MENTIONED | LOW | Rob Black Show Mixed Markets As Inflation Jumps |
Isomorphic is mentioned as having struck partnerships with Eli Lilly. [audio] | +0.5% | +11.7% | +19.8% |
| 2026-05-12 | BUY | MEDIUM | Rob Black Show Stocks Move After High Inflation Reading |
Speaker mentions Eli Lilly's revenue rose 125% year over year due to Monjourno (Mounjaro) and their use of windfalls for acquisitions. [audio] | +3.4% | +17.5% | +24.7% |
| 2026-05-07 | MENTIONED | LOW | Rob Black Show Oil Continues Pullback |
Lilly is mentioned in the context of GLP-1 drugs. [audio] | +3.3% | +16.2% | +20.2% |
| 2026-05-05 | MENTIONED | MEDIUM | Rob Black Show Stocks Get Boost From Oil Pullback |
Barclays raises price target on Lilly. [audio] | +0.1% | +14.0% | +13.6% |
| 2026-05-04 | WATCH | MEDIUM | Rob Black Show Afternoon podcast 5-4-26 |
Host mentions GLP-1s on their 'Lily's pill version' (referring to Eli Lilly) and notes a potential liver problem issue. [audio] | -0.1% | +11.6% | +18.9% |
| 2026-05-01 | MENTIONED | MEDIUM | Rob Black Show Kicking Off May With Record Levels |
Eli Lilly was discussed for its strong performance in GLP-1 drugs, with a 56% revenue boost and a new oral pill for obesity. [audio] | -1.5% | +14.9% | +20.1% |
| 2026-04-30 | BUY | MEDIUM | Rob Black Show Afternoon podcast 4-30-26 |
Eli Lilly was up almost 10% with a decisive earnings beat and the speaker would buy it on dips. [audio] | +4.3% | +18.4% | +29.7% |
| 2026-04-30 | BUY | HIGH | Rob Black Show Markets Working Higher For Now |
Eli Lilly had a monster quarter with revenue and earnings crushing expectations. [audio] | +4.3% | +18.4% | +29.7% |
| 2026-04-27 | MENTIONED | MEDIUM | Rob Black Show The Performance Of Semiconductor Stocks |
Host discusses Eli Lilly deploying cash to acquire Ajax Therapeutics to bolster oncology pipeline. [audio] | +11.5% | +24.9% | +38.0% |
| 2026-04-24 | MENTIONED | MEDIUM | Rob Black Show Focusing On Wealth Accumulation |
Eli Lilly is down 3.8% due to weaker-than-expected drug sales. [audio] | +9.0% | +20.7% | +34.4% |
| 2026-04-22 | BUY | MEDIUM | Rob Black Show Afternoon podcast 4-22-26 |
The host discusses the potential of Eli Lilly's growth and recommends considering it. [audio] | -7.6% | +15.8% | +27.8% |
| 2026-04-21 | MENTIONED | MEDIUM | Rob Black Show Afternoon podcast 4-21-26 |
Eli Lilly and Novo Nordisk stocks tumbling a bit when I say tumble I'm talking about down one and a half to two percent. [audio] | -3.2% | +15.6% | +27.2% |